On September 16, 2024, Allarity Therapeutics, Inc. announced significant progress in its Phase 2 clinical trial for stenoparib, a treatment for advanced, recurrent ovarian cancer. Two patients have now surpassed one year of therapy, demonstrating the drug's potential for durable clinical benefit. The trial, which utilizes Allarity's Drug Response Predictor (DRP) for patient selection, has shown promising results, including a complete response and long-term disease stability in multiple patients. The company's CEO, Thomas H. Jensen, expressed optimism about stenoparib's unique mechanism as both a PARP and Tankyrase inhibitor. The trial's success is attributed to personalized medicine, matching the therapy to the patient's tumor profile. Allarity is planning further development of stenoparib with the aim of accelerating...Show More

On September 16, 2024, Allarity Therapeutics, Inc. announced significant progress in its Phase 2 clinical trial for stenoparib, a treatment for advanced, recurrent ovarian cancer. Two patients have now surpassed one year of therapy, demonstrating the drug's potential for durable clinical benefit. The trial, which utilizes Allarity's Drug Response Predictor (DRP) for patient selection, has shown promising results, including a complete response and long-term disease stability in multiple patients. The company's CEO, Thomas H. Jensen, expressed optimism about stenoparib's unique mechanism as both a PARP and Tankyrase inhibitor. The trial's success is attributed to personalized medicine, matching the therapy to the patient's tumor profile. Allarity is planning further development of stenoparib with the aim of accelerating regulatory approval. The trial is an open-label, single-arm study across the US and UK, where patients are pre-screened with the DRP companion diagnostic. Stenoparib, developed by Allarity and originally by Eisai Co. Ltd., targets PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment. Allarity is focused on advancing personalized cancer treatments and is preparing for the next phase of stenoparib's development.